Novavax | NVAX - Debt


Novavax reported $233.31M in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
Adma Biologics USD 204.41M 121.28M Mar/2026
Agenus USD 35.54M 2.34M Mar/2025
AstraZeneca USD 32.24B 1.68B Jun/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Cassava Sciences USD 0 0 Dec/2024
Geron USD 122.07M 74K Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
MannKind USD 330.96M 36.48M Mar/2026
Merck USD 49.12B 222M Mar/2026
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 1.3B 7M Mar/2026
Novartis USD 47B 14.98B Mar/2026
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 63.19B 536M Jun/2026
Sanofi EUR 23.58B 3.56B Jun/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
TG Therapeutics USD 754.44M 884K Jun/2026